Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

BACKGROUND: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. METHODS: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to A...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Ishii, Takahiro, Kawazoe, Akihito, Sasaki, Akinori, Mishima, Saori, Kentaro, Sawada, Nakamura, Yoshiaki, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Kuwata, Takeshi, Ishii, Genichiro, Shitara, Kohei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7370559/
https://ncbi.nlm.nih.gov/pubmed/32733607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920942377
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak